Vectus Biosystems Ltd. is a drug discovery and development company, which engages in the treatment for fibrosis and high blood pressure, which includes therapeutics for diseases in the fibrotic market namely heart, kidney, and liver disease. Its lead compounds include VB0004, VB4-A32, VB4-A79, and VB4-P5. The company was founded by Karen Duggan on December 12, 2005 and is headquartered in North Ryde, Australia.